The general course of antiviral treatment for hepatitis B major triple yang is 48 weeks if interferon therapy is applied. If hepatitis B virus DNA decreases <2lgIU/mL and hepatitis B surface antigen quantification >2×10^4IU/mL at 24 weeks of interferon treatment, it is recommended to discontinue interferon and change to oral drug therapy. For patients with effective treatment, the course of treatment is 48 weeks, and it can also be extended according to the condition, but should not exceed 96 weeks. There is no fixed course of treatment for those who apply oral antiviral drugs. After 1 year of treatment, if the major triplets turn to minor triplets, transaminases drop to normal and hepatitis B viral DNA is undetectable, consolidation therapy is required for at least 3 more years. During this period, the treatment should be reviewed every 6 months, and those who remain unchanged can be considered for discontinuation and observation.